Shirley Tsunoda

Title(s)Professor Of Clinical, School of Pharmacy and Pharmaceutical Science
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events - A Large Population Database Analysis. Clin Transplant. 2021 Jan 21; e14228. Nguyen VN, Abagyan R, Tsunoda SM. PMID: 33476406.
      View in: PubMed   Mentions:    Fields:    
    2. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transplant. 2020 Oct; 34(10):e14037. Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, Page RL, Tran JN, Aquilante CL. PMID: 32654213.
      View in: PubMed   Mentions:    Fields:    
    3. Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. Clin Transl Sci. 2020 09; 13(5):972-984. Jarmusch AK, Vrbanac A, Momper JD, Ma JD, Alhaja M, Liyanage M, Knight R, Dorrestein PC, Tsunoda SM. PMID: 32216086.
      View in: PubMed   Mentions:    Fields:    
    4. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation. Pharmacogenomics. 2019 12; 20(18):1291-1302. Deininger KM, Tran JN, Tsunoda SM, Young GK, Lee YM, Anderson HD, Page Ii RL, Hirsch JD, Aquilante CL. PMID: 31755847.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Advancing Pharmacist Collaborative Care within Academic Health Systems. Pharmacy (Basel). 2019 Oct 11; 7(4). Awdishu L, Singh RF, Saunders I, Yam FK, Hirsch JD, Lorentz S, Atayee RS, Ma JD, Tsunoda SM, Namba J, Mnatzaganian CL, Painter NA, Watanabe JH, Lee KC, Daniels CD, Morello CM. PMID: 31614555.
      View in: PubMed   Mentions:
    6. Assessing Students' Satisfaction with a Redesigned Pharmacology Course Series. Am J Pharm Educ. 2019 09; 83(7):6971. Brandl K, Schneid SD, Tsunoda SM, Awdishu L. PMID: 31619818.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Initial Development toward Non-Invasive Drug Monitoring via Untargeted Mass Spectrometric Analysis of Human Skin. Anal Chem. 2019 07 02; 91(13):8062-8069. Jarmusch AK, Elijah EO, Vargas F, Bouslimani A, da Silva RR, Ernst M, Wang M, Del Rosario KK, Dorrestein PC, Tsunoda SM. PMID: 31074958.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. J Clin Pharmacol. 2019 11; 59(11):1495-1504. Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS, Nafziger AN, Ma JD. PMID: 31051051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Identification of Maltase Glucoamylase as a Biomarker of Acute Kidney Injury in Patients with Cirrhosis. Crit Care Res Pract. 2019; 2019:5912804. Awdishu L, Tsunoda S, Pearlman M, Kokoy-Mondragon C, Ghassemian M, Naviaux RK, Patton HM, Mehta RL, Vijay B, RamachandraRao SP. PMID: 31179128.
      View in: PubMed   Mentions:
    10. Computational Removal of Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter. J Am Soc Mass Spectrom. 2019 Feb; 30(2):268-277. da Silva RR, Vargas F, Ernst M, Nguyen NH, Bolleddu S, Del Rosario KK, Tsunoda SM, Dorrestein PC, Jarmusch AK. PMID: 30267361.
      View in: PubMed   Mentions:    Fields:    
    11. Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient. Case Rep Transplant. 2018; 2018:7410508. Patel S, Mendler MH, Valasek MA, Tsunoda SM. PMID: 30105113.
      View in: PubMed   Mentions:
    12. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 09; 58(9):1205-1213. Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. PMID: 29663428.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans. J Clin Pharmacol. 2016 07; 56 Suppl 7:S82-98. Momper JD, Tsunoda SM, Ma JD. PMID: 27385182.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    14. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit. 2015 Feb; 37(1):84-9. Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma JD. PMID: 25004135.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping. Drug Metabol Drug Interact. 2013; 28(4):217-23. Tai W, Gong SL, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Stoch SA, Ma JD. PMID: 24114901.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    16. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2012 Jul; 50(7):468-75. Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma JD. PMID: 22541751.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr. 2011 Jan 08; 3:RRN1207. Nguyen CM, Mendes M, Tsunoda S, Ma JD. PMID: 21278901.
      View in: PubMed   Mentions:
    18. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2010 Dec; 48(12):847-53. Ma JD, Nguyen ET, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Lee LS. PMID: 21084040.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010 Apr; 49(4):223-37. Ma JD, Tsunoda SM, Bertino JS, Trivedi M, Beale KK, Nafziger AN. PMID: 20214407.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    20. Cost minimization of medicare part D prescription drug plan expenditures. Am J Manag Care. 2009 Aug; 15(8):545-53. Patel RA, Lipton HL, Cutler TW, Smith AR, Tsunoda SM, Stebbins MR. PMID: 19670958.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    21. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003; 42(13):1071-88. Harris RZ, Jang GR, Tsunoda S. PMID: 14531721.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    22. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002 Apr; 42(4):376-82. Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML, Wilkinson GR, Greenblatt DJ, Bertino JS. PMID: 11936561.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. Independent anchoring and assembly mechanisms of INAD signaling complexes in Drosophila photoreceptors. J Neurosci. 2001 Jan 01; 21(1):150-8. Tsunoda S, Sun Y, Suzuki E, Zuker C. PMID: 11150331.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    24. The organization of INAD-signaling complexes by a multivalent PDZ domain protein in Drosophila photoreceptor cells ensures sensitivity and speed of signaling. Cell Calcium. 1999 Nov; 26(5):165-71. Tsunoda S, Zuker CS. PMID: 10643554.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    25. Specificity in signaling pathways: assembly into multimolecular signaling complexes. Curr Opin Genet Dev. 1998 Aug; 8(4):419-22. Tsunoda S, Sierralta J, Zuker CS. PMID: 9729717.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    26. A multivalent PDZ-domain protein assembles signalling complexes in a G-protein-coupled cascade. Nature. 1997 Jul 17; 388(6639):243-9. Tsunoda S, Sierralta J, Sun Y, Bodner R, Suzuki E, Becker A, Socolich M, Zuker CS. PMID: 9230432.
      View in: PubMed   Mentions: 143     Fields:    Translation:AnimalsCells
    Shirley's Networks
    Concepts (122)
    Derived automatically from this person's publications.
    Co-Authors (25)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department